RBC Capital Maintains Outperform on Axsome Therapeutics, Raises Price Target to $128
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Leonid Timashev maintains an Outperform rating on Axsome Therapeutics (AXSM) and raises the price target from $123 to $128.
March 26, 2024 | 12:09 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
RBC Capital analyst Leonid Timashev maintains an Outperform rating on Axsome Therapeutics and raises the price target from $123 to $128.
The increase in price target by RBC Capital suggests a positive outlook on Axsome Therapeutics' stock, potentially leading to increased investor confidence and a short-term rise in stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100